Somewhat Positive Media Coverage Somewhat Unlikely to Impact Cerus (CERS) Stock Price

News articles about Cerus (NASDAQ:CERS) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cerus earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.2701454671963 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news articles that may have effected Accern Sentiment’s rankings:

Shares of Cerus (NASDAQ CERS) opened at $4.32 on Friday. Cerus has a 1 year low of $1.93 and a 1 year high of $4.70. The company has a debt-to-equity ratio of 0.80, a quick ratio of 3.11 and a current ratio of 3.71. The stock has a market capitalization of $492.85, a PE ratio of -7.32 and a beta of 1.93.

Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.03. The firm had revenue of $10.80 million during the quarter, compared to the consensus estimate of $11.95 million. Cerus had a negative return on equity of 142.18% and a negative net margin of 159.35%. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.14) earnings per share. equities research analysts forecast that Cerus will post -0.57 EPS for the current year.

A number of research firms have issued reports on CERS. Robert W. Baird reissued a “buy” rating and set a $5.00 price target on shares of Cerus in a research report on Friday, December 1st. Cantor Fitzgerald set a $5.00 price target on Cerus and gave the company a “buy” rating in a research report on Monday, January 8th. BidaskClub raised Cerus from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. ValuEngine raised Cerus from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. Finally, BTIG Research reissued a “neutral” rating on shares of Cerus in a research report on Friday, December 8th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $5.83.

ILLEGAL ACTIVITY WARNING: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at

Cerus Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with's FREE daily email newsletter.

Leave a Reply